Bo Wang, MD
Hematology & Oncology · Corvallis, ORNPI 1619357365
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AstraZeneca at 28.3% of the total. 2025 is the largest year on record at $84,023, more than ten times the $5,942 reported in 2019. Among hematology & oncology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $726.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- EMD Serono, Inc.$54K
- Sanofi$37K
- Amgen$16K
- Daiichi Sankyo Inc.$14K
- Genentech USA, Inc.$10K
- plus $49K from 30 others
Across 113 payments — averaging $8395.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$385K
- Puma Biotechnology, Inc.$136K
- Mirati Therapeutics, Inc.$126K
- Genentech, Inc.$106K
- Janssen Research & Development, LLC$79K
- Boehringer Ingelheim$65K
- plus $51K from 4 others
What the payments were for
- Consulting fees$71,17728%
- Speaking & faculty fees$147,00258%
- Travel & lodging$17,4677%
- Food & beverage$15,1246%
- Education$6480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 67 | $71,051 |
| EMD Serono, Inc. | 35 | $54,415 |
| Sanofi | 71 | $36,937 |
| Amgen | 30 | $16,445 |
| Daiichi Sankyo Inc. | 13 | $13,792 |
| Genentech USA, Inc. | 10 | $9,865 |
| Novocure Inc. | 9 | $6,349 |
| Karyopharm Therapeutics Inc. | 3 | $5,743 |
| AbbVie | 9 | $5,520 |
| Lilly USA, LLC | 7 | $4,768 |
| Regeneron | 3 | $4,321 |
| Pfizer | 4 | $4,268 |
| E.r. Squibb & Sons, L.L.C. | 15 | $3,334 |
| Array Biopharma Inc | 3 | $2,520 |
| Janssen Scientific Affairs, LLC | 12 | $1,743 |
| Boehringer Ingelheim International GmbH | 1 | $1,720 |
| Beigene USA, Inc. | 1 | $1,625 |
| Partner Therapeutics, Inc. | 1 | $1,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $891 |
| Genentech, Inc. | 9 | $875 |
| Eli Lilly | 1 | $800 |
| Gilead | 5 | $589 |
| Merck | 7 | $446 |
| GSK | 2 | $425 |
| Seagen Inc. | 4 | $339 |
| Jazz Pharmaceuticals Inc. | 3 | $285 |
| Bayer | 3 | $250 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $244 |
| Foundation Medicine, Inc. | 3 | $185 |
| Reflexion Medical, Inc. | 1 | $156 |
| Bristol Myers Squibb | 2 | $135 |
| Johnson & Johnson | 3 | $102 |
| W. L. Gore & Associates, Inc. | 1 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| AVEO Pharmaceuticals, Inc. | 1 | $81 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$251,417 in reported general payments places this provider in the 95th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 23 | $342,271 |
| Lenalidomide | 20 | $325,438 |
| ImbruvicaIbrutinib | 18 | $294,266 |
| IbrancePalbociclib | 15 | $238,107 |
| TagrissoOsimertinib Mesylate | 14 | $234,946 |
| EliquisApixaban | 68 | $51,469 |
| Letrozole | 186 | $3,664 |
| Abiraterone Acetate | 12 | $1,920 |
| Duloxetine Hcl | 59 | $1,709 |
| Dexamethasone | 98 | $1,662 |
| Oxycodone Hcl | 81 | $1,481 |
| Ondansetron OdtOndansetron | 123 | $1,342 |
| Prochlorperazine Maleate | 109 | $1,102 |
| Morphine Sulfate ErMorphine Sulfate | 31 | $975 |
| Tamoxifen Citrate | 35 | $838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $244 | $294,26618 claims |
| PfizerIbrance, Eliquis | $4,268 | $289,57683 claims |
| AstraZenecaTagrisso | $71,051 | $234,94614 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,743 | $1,92012 claims |
| Lilly USA, LLCOlanzapine | $4,768 | $17019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Corvallis
- Ike OnwereCorvallis$17K
- Keith WellsCorvallis$6K
- Brian DrukerPortland$1.9M
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Christopher YasenchakEugene$102K
- Elie TraerPortland$72K
- Luke FletcherEugene$44K
- Jeffrey MenashePortland$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.